What the Evidence Does NOT Show Because the marketing around these compounds is expansive, it is worth stating explicitly what the published record does not establish: It does not show that cagrilintide is superior, equal, or inferior to tirzepatide no head-to-head trial exists, so any ranking is cross-trial inference
Click HERE to see our Privacy Policy
GLP-1 RAs induce an increase in heart rate (HR), which, theoretically, represents a safety concern, as this is considered to be associated with higher cardiovascular risk [13, 14]
For detailed strategies on managing side effects throughout treatment, see our guide to Ozempic for weight loss, which covers semaglutide side effect management comprehensively
*Disclaimer: Major Players sorted in no particular order Recent Industry Developments December 2025: WHO recommended GLP-1 receptor agonists as part of comprehensive adult-obesity care, citing cardio-metabolic benefits
This knee joint supplement and tendon supplement helps you stay active and perform daily activities with confidence
